Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) today announced financial results for the second quarter ended June 30, 2006. For the three months ended June 30, 2006, the Company reported a net loss of $645,770, or a diluted loss per share of $0.08, compared with a net loss of $184,155, or a diluted loss per share of $0.03 in the prior year. For the six months ended June 30, 2006, the Company reported a net loss of $1,194,541, or a diluted loss per share of $0.15, compared with a net loss of $367,702, or a diluted loss per share of $0.06 in the prior year. The increased loss for such periods resulted primarily from increased clinical development expenses related to IoGen™, salaries and related costs and facility expenses previously allocated to manufacturing, and consulting and other service expenses.
